Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:40 am EST. The presentation is virtual and will be webcast.
The webcast will be available for 90 days via the conference link or Aprea's Investors "News & Events" page. Investors may request 1:1 meetings through their Oppenheimer representative.
Positive
- None.
Negative
- None.
News Market Reaction – APRE
In the Feb 17 session, APRE declined 1.54%, reflecting a mild negative market reaction. Argus tracked a peak move of +34.5% during that session. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Patent expansion | Positive | -3.4% | Expanded global DDR oncology patent estate with protection potentially to 2045. |
| Feb 04 | Management appointment | Positive | -0.5% | Appointed experienced Chief Medical Advisor after early proof-of-concept for APR-1051. |
| Jan 29 | Clinical update | Positive | -22.8% | Reported early proof-of-concept and unconfirmed partial response in ACESOT-1051 trial. |
| Jan 29 | Private placement | Negative | -22.8% | Announced $5.6M private placement with new shares and warrants at $0.89 per unit. |
| Dec 18 | Shareholder letter | Positive | -0.0% | CEO summarized 2025 progress, clinical plans for 2026, and cash runway into Q1 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive corporate, clinical, and IP updates often coincided with flat to negative next-day price moves, with the private placement aligning with a larger selloff.
Over the last few months, APRE highlighted clinical progress for WEE1 inhibitor APR-1051, including early proof-of-concept with a partial response and ongoing dose escalation, and strengthened its DNA damage response patent estate with potential protection into 2045. The company also raised $5.6 million in a private placement and issued a shareholder letter outlining 2026 plans. Despite generally constructive news flow, several of these updates saw negative or muted price reactions, framing today’s conference presentation announcement as part of a broader communication effort.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DOYLESTOWN, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, to take place February 25-26, 2026, virtually.
Presentation Details
| Date/ time: | February 26, 2026 8:40 am EST |
| Location: | Virtual |
| Webcast link: | click here |
The webcast will be available for 90 days at the link above or on the Investors page of the Aprea corporate website, under “News & Events.”
Investors who would like to arrange a 1on1 meeting with Aprea management during the conference should contact their Oppenheimer representative.
About Aprea
Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma.
The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
